BHR-100 Approval Status
FDA Approved: No
Brand name: BHR-100
Generic name: progesterone
Dosage form: Intravenous Infusion
Company: BHR Pharma, LLC
Treatment for: Head Injury
BHR-100 is a proprietary intravenous progesterone infusion product in development as a neuroprotective agent for treating severe traumatic brain injury (TBI) patients.
Development Status and FDA Approval Process for BHR-100
|Sep 3, 2013||BHR Pharma Announces SyNAPSe® Trial Completes Patient Enrollment|
|Dec 8, 2009||BHR Pharma Files Investigational New Drug Application, Receives Orphan Drug Designation, for Traumatic Brain Injury Treatment|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.